Norepinephrine News and Research

RSS

Genetic change in dopamine transporter supports a role for dopamine signaling in ADHD

A genetic change in the dopamine transporter - one of the brain's dopamine-handling proteins - makes it behave as if amphetamine is present and "run backward," Vanderbilt University Medical Center investigators report this week in The Journal of Neuroscience.

9 Jul 2008

Cymbalta approved for fibromyalgia

The U.S. Food and Drug Administration (FDA) has approved Cymbalta (duloxetine HCl) for the management of fibromyalgia, a chronic widespread pain disorder, Eli Lilly and Company announced.

16 Jun 2008

Rochester probes drug therapy, parent training for kids with both autism, ADHD

A National Institutes of Health grant awarded earlier today will empower a team of University of Rochester investigators studying if a blend of drug and behavioral therapy can bring relief to the nearly one-fourth of children with autism who also live with symptoms of ADHD, or attention deficit hyperactivity disorder.

5 Jun 2008

Flow of potassium ions in brain cells is key to sexual arousal

When it comes to sex, a female rat knows how to avoid a communication breakdown. To announce her sexual readiness, she will automatically arch her back, deflect her tail and stand rigid to allow an aroused male to mount.

3 Jun 2008

FDA approves Strattera for ADHD in children and adolescents

Eli Lilly and Company announced today that the United States Food and Drug Administration (FDA) has approved Strattera (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents. Strattera, a selective norepinephrine reuptake inhibitor, is the first FDA-approved non-stimulant to treat ADHD in children, adolescents and adults.

8 May 2008

Aromatherapy and pain relief?

One of the most comprehensive investigations done to date on aromatherapy failed to show any improvement in either immune status, wound healing or pain control among people exposed to two often-touted scents.

4 Mar 2008

FDA approves PRISTIQ for the treatment of adult patients with major depressive disorder

Wyeth Pharmaceuticals, a division of Wyeth, has announced that the U.S. Food and Drug Administration (FDA) has approved PRISTIQ (desvenlafaxine), a structurally novel, once-daily serotonin-norepinephrine reuptake inhibitor (SNRI), to treat adult patients with major depressive disorder (MDD).

3 Mar 2008

New view of human brainstem

A team of scientists from Princeton University has devised a new experimental technique that produces some of the best functional images ever taken of the human brainstem, the most primitive area of the brain.

28 Feb 2008

Comparison of venlafaxine and SSRIs in the treatment of depression

There are numerous antidepressant medications currently on the market, but sadly, many patients still experience the debilitating symptoms of depression even with treatment.

21 Feb 2008

Antidepressants might be worthless for treating low back pain

The review appears in the latest issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic.

30 Jan 2008

Duloxetine does not relieve painful physical symptoms in depression

An analysis of the data which are available, published in the European Journal Psychotherapy and Psychosomatics, discloses that the maker's claims are not warranted.

22 Jan 2008

Stress causes whole body deterioration

Stress, to put it bluntly, is bad for you. It can kill you, in fact. A study now reveals that stress causes deterioration in everything from your gums to your heart and can make you more susceptible to everything from the common cold to cancer.

9 Jan 2008

Venlafaxine extended-release effective for patients with major depression

Major depressive disorder (MDD) is the most common major mental illness, afflicting almost one in five individuals.

13 Dec 2007

New strategy for developing antidepressants

Researchers may be able to develop an antidepressant which takes effect almost immediately by directly targeting novel molecules in the brain instead of taking a less direct route, which can lead to longer times for medication to take effect, according to a new study presented at the American College of Neuropsychopharmacology (ACNP) annual meeting.

10 Dec 2007